UBS Group’s Generate Biomedicines GENB Stock Holding History

UBS Group’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.5M	Sell	326,273 -30,431	-9%	-$415K	﹤0.01%	4071
2026 Q1	$4.46M	Buy	+356,704	New	+$4.36M	﹤0.01%	4189

Other funds holding GENB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

UBS Group's GENB Position: Q2 2026 in Review

UBS Group reduced its Generate Biomedicines (GENB) stake by 8.5% in Q2 2026, selling an estimated $415K and leaving 326,273 shares worth $5.5M. The position accounts for ﹤0.01% of the portfolio, ranked #4071.

UBS Group first reported a position in GENB in Q1 2026 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

UBS Group held 326,273 shares of Generate Biomedicines worth $5.5M as of Q2 2026.
UBS Group sold 30,431 Generate Biomedicines shares in Q2 2026, an estimated $415K.
Generate Biomedicines made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4071 holding.
UBS Group first reported a position in Generate Biomedicines in Q1 2026 and has held it in 2 quarters since.
86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.